Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma
Authors
Keywords
-
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 157, Issue -, Pages 113963
Publisher
Elsevier BV
Online
2022-11-16
DOI
10.1016/j.biopha.2022.113963
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
- (2020) Kira Allmeroth et al. LEUKEMIA
- Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
- (2019) Pawel Robak et al. Drugs in research & development
- Proteasome inhibition in multiple myeloma: lessons for other cancers
- (2019) Paula Saavedra-García et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Spectrum and functional validation of PSMB5 mutations in multiple myeloma
- (2018) Santiago Barrio et al. LEUKEMIA
- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- Ixazomib: First Global Approval
- (2016) Matt Shirley DRUGS
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
- (2016) G P Soriano et al. LEUKEMIA
- Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
- (2016) Peter Tsvetkov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The inhibition mechanism of human 20Sproteasomes enables next-generation inhibitor design
- (2016) Jil Schrader et al. SCIENCE
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- g_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations
- (2014) Rashmi Kumari et al. Journal of Chemical Information and Modeling
- Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2013) Jennifer L Thompson ANNALS OF PHARMACOTHERAPY
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
- (2013) G. Madhavi Sastry et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method
- (2012) Nadine Homeyer et al. Molecular Informatics
- Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
- (2011) N E Franke et al. LEUKEMIA
- The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
- (2010) Di Chen et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Identifying and Characterizing Binding Sites and Assessing Druggability
- (2009) Thomas A. Halgren Journal of Chemical Information and Modeling
- The proteasome: Overview of structure and functions
- (2009) Keiji TANAKA PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now